118 related articles for article (PubMed ID: 25574617)
1. Foundation receives $3.3-billion windfall for Kalydeco.
Senior M
Nat Biotechnol; 2015 Jan; 33(1):8-9. PubMed ID: 25574617
[No Abstract] [Full Text] [Related]
2. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
Kaiser J
Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
[No Abstract] [Full Text] [Related]
3. Hot off the breath: 'I've a cost for'--the 64 million dollar question.
Bush A; Simmonds NJ
Thorax; 2012 May; 67(5):382-4. PubMed ID: 22407889
[No Abstract] [Full Text] [Related]
4. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding.
Cohen D; Raftery J
BMJ; 2014 Feb; 348():g1445. PubMed ID: 24523379
[No Abstract] [Full Text] [Related]
5. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
6. The evidence for long-term benefits of restoration of CFTR function continues to grow.
Boyle MP
Am J Respir Crit Care Med; 2015 Oct; 192(7):774-6. PubMed ID: 26426780
[No Abstract] [Full Text] [Related]
7. Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis.
Kounis I; Lévy P; Rebours V
Am J Gastroenterol; 2018 Jul; 113(7):1058-1059. PubMed ID: 29887601
[No Abstract] [Full Text] [Related]
8. Cystic fibrosis drug is not cost effective, says NICE.
Gulland A
BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
[No Abstract] [Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
10. Cystic Fibrosis Trust's clarification of Cohen and Raftery's article on cystic fibrosis drug development.
Owen E
BMJ; 2014 Mar; 348():g1849. PubMed ID: 24603568
[No Abstract] [Full Text] [Related]
11. Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.
Heltshe SL; Rowe SM; Skalland M; Baines A; Jain M;
Am J Respir Crit Care Med; 2018 Jun; 197(11):1483-1486. PubMed ID: 29256624
[No Abstract] [Full Text] [Related]
12. Precision Medicine: At What Price?
Ferkol T; Quinton P
Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
[No Abstract] [Full Text] [Related]
13. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
14. Therapy for cystic fibrosis--the end of the beginning?
Davis PB
N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
[No Abstract] [Full Text] [Related]
15. Ivacaftor in a G551D homozygote with cystic fibrosis.
Harrison MJ; Murphy DM; Plant BJ
N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
[No Abstract] [Full Text] [Related]
16. A new model for drug development using a multi-stakeholder consortium.
Hall AK
BMJ; 2014 Mar; 348():g1850. PubMed ID: 24603569
[No Abstract] [Full Text] [Related]
17. Settlement reached over medicaid coverage of cystic fibrosis drug: Arkansas federal court case highlights medical necessity, high cost of targeted therapies.
Am J Med Genet A; 2015 Apr; 167A(4):viii-ix. PubMed ID: 25820402
[No Abstract] [Full Text] [Related]
18. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Tümmler B
Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
[No Abstract] [Full Text] [Related]
19. Ivacaftor (Kalydeco) for cystic fibrosis.
Med Lett Drugs Ther; 2012 Apr; 54(1388):29-30. PubMed ID: 22499233
[No Abstract] [Full Text] [Related]
20. Cystic fibrosis drug Vertex's latest triumph.
Ledford H
Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
[No Abstract] [Full Text] [Related]
[Next] [New Search]
